Simulations Plus Inc Overview
Industry: Health Information Services
Sector: Healthcare
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems toxicology software; NAFLDsym; IPFsym; RENAsym; IPFsym; and MITOsym. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was incorporated in 1996 and is headquartered in Lancaster, California. Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers G Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Simulations Plus Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $21.9M (+100% YoY); EPS was $21.9 (reported).
Revenue
$21.9M
+100% YoY
EPS
$21.9
reported
Net income
$3.6M
+16% YoY
Adjusted EBITDA
$7.9
reported
What changed
- Revenue +100% YoY to $21.9M; EPS reported to $21.9.
- Net income +16% YoY to $3.6M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings material
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Jul 09, 2026
SEC filing
8-K
Jul 09, 2026
Earnings release
Earnings release
Jul 09, 2026
SEC filing
10-Q
Apr 10, 2026
Earnings material
Earnings release
Apr 09, 2026
Earnings release
Earnings release
Apr 09, 2026
SEC filing
8-K
Apr 09, 2026
SEC filing
10-Q
Jan 09, 2026
SEC filing
8-K
Jan 08, 2026
Earnings material
Earnings release
Jan 08, 2026
Earnings material
Earnings release
Jan 08, 2026
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Headline from GlobeNewswire: Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures.
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG
Headline from PR Newswire: $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG.
Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold
Headline from Seeking Alpha: Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold.
Earnings Per Share
Score 2.00/5
Simulations Plus Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Health Information Services industry
, National Research Corp
, HealthStream Inc
, VEEVA SYSTEMS INC
are companies with high ratings.
Return on Equity
Score 2.26/5
Simulations Plus Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 3.89/5
Simulations Plus Inc
commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 4.00/5
Simulations Plus Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios